ARTV
Artiva Biotherapeutics, Inc.Healthcare · $528M market cap
Verdict
We can't put a fair value on ARTV right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow ARTV
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
1 of the investors we track holds ARTV. In Q2 2026, 1 opened a position. Who we track
Moves in Q2 2026
New position: Viking Global Investors
Insider activity
Since Sep 3, 2026: no open-market purchases, 5 sales worth $1.2M and 15 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Aslan Fred
Chief Executive Officer · 2026-09-08
Sold
$256K
Aslan Fred
Chief Executive Officer · 2026-09-03
Sold
$690K
Banerjee Subhashis
Chief Medical Officer · 2026-09-03
Sold
$12K
Bush Jennifer
COO, CLO, Compliance Officer · 2026-09-03
Sold
$94K
Horan Christopher
Chief Tech Operations Officer · 2026-09-03
Sold
$116K
Other filings
Banerjee Subhashis
Chief Medical Officer · 2026-09-09
Award
$917K
Banerjee Subhashis
Chief Medical Officer · 2026-09-09
Award
30,000 shares
Bush Jennifer
COO, CLO, Compliance Officer · 2026-09-09
Award
$1.5M
Bush Jennifer
COO, CLO, Compliance Officer · 2026-09-09
Award
45,000 shares
Horan Christopher
Chief Tech Operations Officer · 2026-09-09
Award
$1.3M
Show all 15 other filingsShow fewer
Miralles Gines Diego
President & Head of R&D · 2026-09-09
Award
$1.5M
Miralles Gines Diego
President & Head of R&D · 2026-09-09
Award
45,000 shares
Horan Christopher
Chief Tech Operations Officer · 2026-09-09
Award
40,000 shares
MOORE ALISON
director · 2026-09-08
Award
$150K
Baker Daniel G.
director · 2026-09-08
Award
$150K
DANIELS BRIAN
director · 2026-09-08
Award
$150K
HOUGEN ELIZABETH L
director · 2026-09-08
Award
$150K
Sorg Elaine K.
director · 2026-09-08
Award
$150K
Stoppel Laura
director · 2026-09-08
Award
$150K
RA CAPITAL MANAGEMENT, L.P.
director · 2026-09-08
Award
$150K
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works